A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment
Clinical trial NCT01082315 · COMPLETED
Trial details
- NCT number
- NCT01082315
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2009-04-01
- Primary completion
- 2014-07-01
- Enrollment
- 730
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.